Aclarion

Aclarion EPS

The Earnings per Share (EPS) of Aclarion (ACON) as of Oct 20, 2026 is -13.60 USD. In the previous year, Earnings per Share (EPS) was -4,994.95 USD — a change of -99.73% (higher).

EPS

-13.60USD

YoY

-99.73%

Last updated:

Earnings per Share (EPS) of Aclarion is 2025 -13.60 USD. Earnings per Share (EPS) of Aclarion was 2024 -4,994.95 USD. It decreases by -99.73% higher compared to the previous year.

The Aclarion EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS
Date
EPS
Jan 1, 2019
-1.63 USD
Jan 1, 2022
-70,685.93 USD
Jan 1, 2023
-49,113.74 USD
Jan 1, 2024
-4,994.95 USD
Jan 1, 2025
-13.60 USD
Jan 1, 2026 (e)
-4.51 USD
Jan 1, 2027 (e)
-5.47 USD
The Aclarion EPS history
YEAREPSYoY
est-5.47USD+21.29%
est-4.51USD-66.83%
-13.60USD-99.73%
-4,994.95USD-89.83%
-49,113.74USD-30.52%
-70,685.93USD+4.33 M%
-1.63USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aclarion Stock analysis

What does Aclarion do? Aclarion, Inc. generates revenue through its proprietary biomarker technology and signal processing software, which transforms raw Magnetic Resonance Spectroscopy (MRS) data into metabolic biomarkers for clinical use. The company's products are utilized by physicians to differentiate between painful and nonpainful lumbar spine discs, leveraging augmented intelligence in post-processing algorithms to quantify biomarker data and produce individualized ratio metrics against normative datasets. The firm targets healthcare providers focused on chronic low back pain treatment, offering solutions that optimize clinical decision-making through metabolic analysis. Aclarion's technology is centered on Magnetic Resonance Spectroscopy (MRS) and its proprietary biomarker, designed to assist physicians in determining disc-related pain in the lumbar spine. The company's signal processing software and expert system convert raw spectral MRS data into clear, actionable biomarkers, enabling tailored treatment approaches for chronic low back pain patients. By focusing exclusively on this clinical application, Aclarion serves a specialized segment of healthcare providers seeking advanced diagnostic tools for spinal conditions. Aclarion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aclarion stock

Earnings per Share (EPS) of Aclarion is -13.60 USD in 2025.

Earnings per Share (EPS) of Aclarion changed from -4,994.95 USD to -13.60 USD, representing a -99.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Earnings per Share (EPS) Aclarion since 2006 – with annual values, charts, and detailed analysis.

Earnings per Share measures the portion of a company's profit allocated to each outstanding share. It is a key metric for assessing a company's profitability on a per-share basis.

EPS = Net Income / Shares Outstanding

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Aclarion

All Key Metrics — Aclarion